BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23008318)

  • 1. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.
    Haugnes HS; Bosl GJ; Boer H; Gietema JA; Brydøy M; Oldenburg J; Dahl AA; Bremnes RM; Fosså SD
    J Clin Oncol; 2012 Oct; 30(30):3752-63. PubMed ID: 23008318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
    van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors.
    Haugnes HS; Oldenburg J; Bremnes RM
    Urol Oncol; 2015 Sep; 33(9):399-406. PubMed ID: 25554583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Morbidity of Testicular Cancer Treatment.
    Fung C; Fossa SD; Williams A; Travis LB
    Urol Clin North Am; 2015 Aug; 42(3):393-408. PubMed ID: 26216826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequelae of treatment in long-term survivors of testis cancer.
    Abouassaly R; Fossa SD; Giwercman A; Kollmannsberger C; Motzer RJ; Schmoll HJ; Sternberg CN
    Eur Urol; 2011 Sep; 60(3):516-26. PubMed ID: 21684072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of advanced testicular cancer.
    Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
    JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term complications following treatment of testicular cancer and Hodgkin lymphoma].
    van den Belt-Dusebout AW; Aleman BM; Gietema JA; de Wit R; van 't Veer MB; Lugtenburg PJ; Krol AD; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2010; 154(45):A2229. PubMed ID: 21118593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term morbidity after treatment for testicular cancer.
    Fosså SD; Oldenburg J; Dahl AA
    BJU Int; 2009 Nov; 104(9 Pt B):1418-22. PubMed ID: 19840023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
    Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
    J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The graying of testis cancer patients: what have we learned?
    Bajorin DF
    J Clin Oncol; 2007 Oct; 25(28):4341-3. PubMed ID: 17906197
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship.
    Christensen JF; Bandak M; Campbell A; Jones LW; Højman P
    Acta Oncol; 2015 May; 54(5):592-9. PubMed ID: 25751759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary malignant neoplasms in testicular cancer survivors.
    Curreri SA; Fung C; Beard CJ
    Urol Oncol; 2015 Sep; 33(9):392-8. PubMed ID: 26072728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients.
    Suarez-Ibarrola R; Abufaraj M; Shariat SF
    Curr Opin Urol; 2018 Sep; 28(5):485-490. PubMed ID: 30044319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment.
    Tukenova M; Diallo I; Hawkins M; Guibout C; Quiniou E; Pacquement H; Dhermain F; Shamsaldin A; Oberlin O; de Vathaire F
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):707-15. PubMed ID: 20200431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis].
    Bokemeyer C; Kuczyk MA; Köhne CH; Haupt A; Schmoll HJ
    Med Klin (Munich); 1996 Nov; 91(11):703-10. PubMed ID: 9036294
    [No Abstract]   [Full Text] [Related]  

  • 16. Testicular cancer patients: considerations in long-term follow-up.
    Gospodarowicz M
    Hematol Oncol Clin North Am; 2008 Apr; 22(2):245-55, vi. PubMed ID: 18395148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term toxicity of the treatment for germ cell-cancer. A review.
    Maroto P; Anguera G; Martin C
    Crit Rev Oncol Hematol; 2018 Jan; 121():62-67. PubMed ID: 29279100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of late complications of treatment and late relapse in testicular cancer.
    Efstathiou E; Logothetis CJ
    J Natl Compr Canc Netw; 2006 Nov; 4(10):1059-70. PubMed ID: 17112453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of treatment of germ cell tumors.
    Boyer M; Raghavan D
    Semin Oncol; 1992 Apr; 19(2):128-42. PubMed ID: 1313191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
    Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
    Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.